Drugs / DermaBind TL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT07172893 | Dec 2025 → Feb 2027 expected | ulcer of lower limbs | HealthTech Wound Care | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DermaBind TL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07172893 ↗ |
| Modality | Other / unclassified | “Full-Thickness Dehydrated Placental Allograft” NCT07172893 ↗ |
| Route | Topical | “The treatment period will be 12 weeks, during which DermaBind TL™ will be applied to the affected wound.” NCT07172893 ↗ |